Drugs / Volixibat
Volixibat
also known as
SHP626 · LUM-002 · SAR-548304 · SAR-548304 FREE ACID · Volixibat (SHP626) · VOLIXIBAT POTASSIUM
Small molecule targets SLC10A2 via inhibition
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02571192 | Oct 2015 | metabolic dysfunction-associated steatohepatitis | Mirum Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02475317 | Jun → Dec 2015 | — | Mirum Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02287779 | Jan → Jun 2015 | metabolic dysfunction-associated steatohepatitis | Mirum Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05050136 | Sep 2021 → Apr 2027 expected | primary biliary cholangitis | Mirum Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04718961 | Jan 2021 → Dec 2022 | intrahepatic cholestasis of pregnancy | Mirum Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04663308 | Dec 2020 → Jun 2026 overdue | primary sclerosing cholangitis | Mirum Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02787304 | Oct 2016 → Jul 2018 | metabolic dysfunction-associated steatohepatitis | Mirum Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-07-29 | Takeda | Shire’s SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults who have Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis takeda.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Volixibat | “A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults:...” PMID 29548345 ↗ Mar 20185“Volixibat is a potent inhibitor of the apical sodium-dependent bile acid transporter in development for the treatment of nonalcoholic steatohepatitis.” PMID 28702877 ↗ Feb 2018 |
| Known as | LUM-002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707222 ↗ |
| Known as | SAR-548304 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707222 ↗ |
| Known as | SAR-548304 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707222 ↗ |
| Known as | SHP626 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02787304 ↗ |
| Known as | Volixibat (SHP626) | “Volixibat (SHP626)” NCT02787304 ↗ |
| Known as | VOLIXIBAT POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707222 ↗ |
| Action | Inhibit | “Ileal bile acid transporter inhibitor” CHEMBL3707222 ↗1“Volixibat inhibits bile acid reuptake” PMID 29548345 ↗ Mar 2018 |
| Modality | Small molecule | — CHEMBL3707222 ↗ |
| Route | Oral | “Multiple Oral Doses of SHP626” NCT02287779 ↗ |
| Target | SLC10A2 | “Ileal bile acid transporter inhibitor” CHEMBL3707222 ↗ |